Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Aug;109(4):1133–1139. doi: 10.1111/j.1476-5381.1993.tb13740.x

Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats.

N E Bowring 1, J R Arch 1, D R Buckle 1, J F Taylor 1
PMCID: PMC2175747  PMID: 8401925

Abstract

1. BRL 55834, a novel potassium channel activator, has been compared with levcromakalim (BRL 38227) for its relaxant effects in vivo on the airways and vasculature of the guinea-pig and rat. 2. When administered intravenously 2 min prior to challenge, BRL 55834 and levcromakalim each inhibited histamine-induced increases in airways resistance (Raw) in the anaesthetized guinea-pig, with BRL 55834 showing a 4.5 fold greater potency than levcromakalim (ED25 = 2.5 micrograms kg-1 and 11.3 micrograms kg-1 respectively). By contrast, both compounds had similar hypotensive potencies (ED18 = 8.5 micrograms kg-1 and 6.5 micrograms kg-1 respectively). 3. In the same guinea-pig model, intraduodenally administered BRL 55834 (100 and 250 micrograms kg-1) and levcromakalim (500 micrograms kg-1) each protected against histamine-induced changes in Raw and dynamic lung compliance (Cdyn), both compounds showing a rapid onset of action that persisted for more than 50 min. The lower dose of BRL 55834 had a similar bronchodilator effect to that of levcromakalim, yet both doses of BRL 55834 elicited substantially smaller effects than levcromakalim on mean arterial blood pressure. 4. In the anaesthetized rat, BRL 55834 and levcromakalim each evoked a dose-related inhibition of inhaled methacholine-induced changes in Raw and Cdyn when given i.v., with BRL 55834 showing some four fold greater potency than levcromakalim (BRL 55834: Raw ED35 = 3.7 micrograms kg-1, Cdyn ED35 = 5.9 micrograms kg-1; levcromakalim: Raw ED35 = 16 micrograms kg-1, Cdyn ED35 = 23.5 micrograms kg-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1139

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arch J. R., Buckle D. R., Bumstead J., Clarke G. D., Taylor J. F., Taylor S. G. Evaluation of the potassium channel activator cromakalim (BRL 34915) as a bronchodilator in the guinea-pig: comparison with nifedipine. Br J Pharmacol. 1988 Nov;95(3):763–770. doi: 10.1111/j.1476-5381.1988.tb11702.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bowring N. E., Buckle D. R., Clarke G. D., Taylor J. F., Arch J. R. Evaluation of the potassium channel activator BRL 38227 as an inhaled bronchodilator in the guinea-pig: contrast with nifedipine and salbutamol. Pulm Pharmacol. 1991;4(2):99–105. doi: 10.1016/0952-0600(91)90059-c. [DOI] [PubMed] [Google Scholar]
  3. Buckle D. R., Arch J. R., Bowring N. E., Foster K. A., Taylor J. F., Taylor S. G., Shaw D. J. Relaxant effects of the potassium channel activators BRL 38227 and pinacidil on guinea-pig and human airway smooth muscle, and blockade of their effects by glibenclamide and BRL 31660. Pulm Pharmacol. 1993 Mar;6(1):77–86. doi: 10.1006/pulp.1993.1011. [DOI] [PubMed] [Google Scholar]
  4. Burka J. F., Berry J. L., Foster R. W., Small R. C., Watt A. J. Effects of cromakalim on neurally-mediated responses of guinea-pig tracheal smooth muscle. Br J Pharmacol. 1991 Sep;104(1):263–269. doi: 10.1111/j.1476-5381.1991.tb12417.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chapman I. D., Kristersson A., Mathelin G., Schaeublin E., Mazzoni L., Boubekeur K., Murphy N., Morley J. Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol. 1992 Jun;106(2):423–429. doi: 10.1111/j.1476-5381.1992.tb14350.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Souza R. N., Gater P. R., Alabaster V. A. Bronchodilator and tracheal relaxant effects of potassium channel openers in the guinea-pig. Br J Pharmacol. 1989 Dec;98 (Suppl):803P–803P. [PubMed] [Google Scholar]
  7. Englert H. C., Wirth K., Gehring D., Fürst U., Albus U., Scholz W., Rosenkranz B., Schölkens B. A. Airway pharmacology of the potassium channel opener, HOE 234, in guinea pigs: in vitro and in vivo studies. Eur J Pharmacol. 1992 Jan 7;210(1):69–75. doi: 10.1016/0014-2999(92)90653-l. [DOI] [PubMed] [Google Scholar]
  8. Good D. M., Clapham J. C., Hamilton T. C. Effects of BRL 38227 on neurally-mediated responses in the guinea-pig isolated bronchus. Br J Pharmacol. 1992 Apr;105(4):933–940. doi: 10.1111/j.1476-5381.1992.tb09081.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ichinose M., Barnes P. J. A potassium channel activator modulates both excitatory noncholinergic and cholinergic neurotransmission in guinea pig airways. J Pharmacol Exp Ther. 1990 Mar;252(3):1207–1212. [PubMed] [Google Scholar]
  10. Kallós P., Kallós L. Experimental asthma in guinea pigs revisited. Int Arch Allergy Appl Immunol. 1984;73(1):77–85. doi: 10.1159/000233441. [DOI] [PubMed] [Google Scholar]
  11. Longman S. D., Hamilton T. C. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential. Med Res Rev. 1992 Mar;12(2):73–148. doi: 10.1002/med.2610120202. [DOI] [PubMed] [Google Scholar]
  12. Noack T., Deitmer P., Edwards G., Weston A. H. Characterization of potassium currents modulated by BRL 38227 in rat portal vein. Br J Pharmacol. 1992 Jul;106(3):717–726. doi: 10.1111/j.1476-5381.1992.tb14400.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Paciorek P. M., Burden D. T., Burke Y. M., Cowlrick I. S., Perkins R. S., Taylor J. C., Waterfall J. F. Preclinical pharmacology of Ro 31-6930, a new potassium channel opener. J Cardiovasc Pharmacol. 1990 Feb;15(2):188–197. doi: 10.1097/00005344-199002000-00003. [DOI] [PubMed] [Google Scholar]
  14. Paciorek P. M., Burden D. T., Gater P. R., Hawthorne Y. M., Spence A. M., Taylor J. C., Waterfall J. F. Inhibition by Ro 31-6930 of agonist and allergen induced bronchoconstriction in anaesthetised guinea-pigs and cats. Pulm Pharmacol. 1991;4(4):225–232. doi: 10.1016/0952-0600(91)90015-u. [DOI] [PubMed] [Google Scholar]
  15. Paciorek P. M., Cowlrick I. S., Perkins R. S., Taylor J. C., Wilkinson G. F., Waterfall J. F. Evaluation of the bronchodilator properties of Ro 31-6930, a novel potassium channel opener, in the guinea-pig. Br J Pharmacol. 1990 Jun;100(2):289–294. doi: 10.1111/j.1476-5381.1990.tb15797.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Raeburn D., Karlsson J. A. Potassium channel openers: airway pharmacology and clinical possibilities in asthma. Prog Drug Res. 1991;37:161–180. doi: 10.1007/978-3-0348-7139-6_4. [DOI] [PubMed] [Google Scholar]
  17. Rogers D. F., Aursudkij B., Barnes P. J. Effects of tachykinins on mucus secretion in human bronchi in vitro. Eur J Pharmacol. 1989 Dec 19;174(2-3):283–286. doi: 10.1016/0014-2999(89)90322-1. [DOI] [PubMed] [Google Scholar]
  18. Small R. C., Berry J. L., Burka J. F., Cook S. J., Foster R. W., Green K. A., Murray M. A. Potassium channel activators and bronchial asthma. Clin Exp Allergy. 1992 Jan;22(1):11–18. doi: 10.1111/j.1365-2222.1992.tb00109.x. [DOI] [PubMed] [Google Scholar]
  19. Taylor S. G., Arch J. R., Bond J., Buckle D. R., Shaw D. J., Taylor J. F., Ward J. S. The inhibitory effects of cromakalim and its active enantiomer BRL 38227 against various agonists in guinea pig and human airways: comparison with pinacidil and verapamil. J Pharmacol Exp Ther. 1992 May;261(2):429–437. [PubMed] [Google Scholar]
  20. Williams A. J., Lee T. H., Cochrane G. M., Hopkirk A., Vyse T., Chiew F., Lavender E., Richards D. H., Owen S., Stone P. Attenuation of nocturnal asthma by cromakalim. Lancet. 1990 Aug 11;336(8711):334–336. doi: 10.1016/0140-6736(90)91877-d. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES